Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avigen’s neuropathic pain drug shows promising results
In this preliminary efficacy trial there appears to be no difference in overall mean visual analog scale (VAS) scores between active and placebo arms, a pharmacokinetic assessment indicates
In this preliminary efficacy trial there appears to be no difference in overall mean visual analog scale (VAS) scores between active and placebo arms, a pharmacokinetic assessment indicates
The three physicians practicing as part of Desert Neonatal Medical Group staff the 30-bed neonatal intensive care unit (NICU) at Desert Regional Medical Center, which has annual patient
The study results support RB007’s ability to reverse the anticoagulant effect of RB006 either completely or partially, depending on the level of dosing of RB007. The study showed
The transaction includes Fiserv Health, a leading administrator of medical benefits, Avidyn Health, a care facilitation business, and the Fiserv Health Specialty Solutions businesses, which include J.W. Hutton,
Bill Hawkins, president and CEO of Medtronic, said: “The product lines and the geographic presence of these two companies are highly complementary. We expect this acquisition to help
The purpose built facility will include an expanded manufacturing plant with initial capacity sufficient to supply Bronchitol to approximately 40,000 patients per year. Pharmaxis is developing Bronchitol for
Studies 102 and 103 compare Viread to Gilead’s Hepsera (adefovir dipivoxil) among patients with HBeAg-negative (presumed pre-core mutant) chronic hepatitis B and patients with HBeAg-positive hepatitis B, respectively.
This phase II randomized, controlled trial was conducted at two centers in Egypt and is part of the company’s STEALTH C (studies to evaluate Alinia for treatment of
The study is designed as a prospective, multicenter, randomized trial comparing InterStim therapy to standard medical management for patients with symptoms of overactive bladder, including urinary urge incontinence
Patients in this cohort were nucleoside naive e-antigen (HBeAg)-positive patients with chronic hepatitis B infection. HBeAg is a viral protein identified as a marker of active replication of